Buy & Sell Newmont Corporation (NEM) – Newmont Corporation Price Today
Aura AI Summary
Key Stats
- $124.38BMarket Cap
- Basic MaterialsSector
- -26.31%3M Drawdown
- $121.13BEnterprise Value
- 0.89%Dividend Yield
- 14% Buy | 86% SellTrading Activity
- 47 daysTypical Hold Time
Newmont Corporation (NEM) is currently valued at a market capitalization of $124.38B, with an enterprise value of $121.13B. Over the past 52 weeks, Newmont Corporation has traded between a low of $48.66 and a high of $131.95, highlighting its annual price range. Over the past three months, Newmont Corporation has recorded a drawdown of -26.31%, reflecting recent price volatility. Newmont Corporation offers a dividend yield of 0.89%, with the most recent dividend of $0.26 paid on 03 Mar 26. On average, investors hold Newmont Corporation for approximately 47 days, indicating typical investor behavior on the platform.
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Most Recent News
Nvidia commits $40B to AI investments in early 2026, including $30B in OpenAI
Nvidia has invested over $40 billion in AI-related equity deals in early 2026, with a major $30 billion stake in OpenAI. The company also made multi-billion dollar investments in public firms like Corning and IREN, signaling strong confidence in the ...
Investor Michael Burry warns AI stock craze mirrors late 1990s Dot-com bubble risks.
Michael Burry, known for predicting the 2008 housing crash, warns that the current stock market rally driven by enthusiasm for AI-related companies resembles the late 1990s Dot-com bubble. Despite economic uncertainty, major U.S. indexes keep hitting...
BioVie nears data readout for potential first treatment targeting long COVID symptoms.
BioVie Inc is advancing its clinical trial for a novel treatment aimed at long COVID, a condition affecting around 17 million Americans with symptoms like brain fog and fatigue. The company has secured a $13 million grant, making it unique in receivi...